Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Biocept, Inc. (BIOC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.4900+0.0700 (+4.93%)
At close: 04:00PM EDT
1.5100 +0.02 (+1.34%)
After hours: 06:51PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4200
Open1.4000
Bid1.4500 x 1800
Ask1.5100 x 4000
Day's Range1.4000 - 1.4900
52 Week Range1.4000 - 4.9700
Volume44,216
Avg. Volume113,209
Market Cap25.095M
Beta (5Y Monthly)0.48
PE Ratio (TTM)6.80
EPS (TTM)0.2190
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
  • Business Wire

    Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q

    SAN DIEGO, May 16, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a delay in the filing of its Quarterly Report on Form 10-Q for the three months ended March 31, 2022. The delay is related to the ongoing accounting review of Biocept’s financial statements as of and for the three months ended March 31, 2022, which ongoing review is a result of a change in circumstances at the U.S. Health Resources Services Administration (HR

  • Business Wire

    Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 08, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 519,140 shares of its common stock to 44 new employees, including an inducement stock option to purchase 150,000 shares of its common stock to Philippe Marchand, Ph.D., its new Chief Operations Officer. The inducement stock options have a grant date of March 31, 2022, and were gr

  • Business Wire

    Biocept Reports 2021 Fourth Quarter and Full Year Financial Results

    SAN DIEGO, April 06, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and 12 months ended December 31, 2021 and provides a business update.

Advertisement
Advertisement